title: Fas/FasL in the immune pathogenesis of severe aplastic anemia.
abstract: Fas/FasL protein expression of bone marrow hematopoietic cells was investigated in severe aplastic anemia (SAA) patients. Fas expression was evaluated in CD34(+), GlycoA(+), CD33(+), and CD14(+) cells labeled with monoclonal antibodies in newly diagnosed and remission SAA patients along with normal controls. FasL expression was evaluated in CD8(+) cells in the same manner. In CD34(+) cells, Fas expression was significantly higher in the newly diagnosed SAA group (46.59 ± 27.60%) than the remission (6.12 ± 3.35%; P < 0.01) and control (8.89 ± 7.28%; P < 0.01) groups. In CD14(+), CD33(+), and GlycoA(+) cells, Fas levels were significantly lower in the newly diagnosed SAA group (29.29 ± 9.23, 46.88 ± 14.30, and 15.15 ± 9.26%, respectively) than in the remission (47.23 ± 31.56, 67.22 ± 34.68, and 43.56 ± 26.85%, respectively; P < 0.05) and normal control (51.25 ± 38.36, 72.06 ± 39.88, 50.38 ± 39.88%, respectively; P < 0.05) groups. FasL expression of CD8(+) cells was significantly higher in the newly diagnosed SAA group (89.53 ± 45.68%) than the remission (56.39 ± 27.94%; P < 0.01) and control (48.63 ± 27.38%; P <0.01) groups. No significant differences were observed between the remission and control groups. FasL expression in CD8(+) T cells was significantly higher in newly diagnosed patients, and CD34(+), CD33(+), CD14(+), and GlycoA(+) cells all showed Fas antigen expression. The Fas/FasL pathway might play an important role in excessive hematopoietic cell apoptosis in SAA bone marrow. Furthermore, CD34(+) cells are likely the main targets of SAA immune injury.
authors.affiliation: Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
authors.forename: C Y
authors.initials: CY
authors.lastname: Liu
authors.affiliation: Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
authors.forename: R
authors.initials: R
authors.lastname: Fu
authors.affiliation: Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
authors.forename: H Q
authors.initials: HQ
authors.lastname: Wang
authors.affiliation: Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
authors.forename: L J
authors.initials: LJ
authors.lastname: Li
authors.affiliation: Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
authors.forename: H
authors.initials: H
authors.lastname: Liu
authors.affiliation: Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
authors.forename: J
authors.initials: J
authors.lastname: Guan
authors.affiliation: Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
authors.forename: T
authors.initials: T
authors.lastname: Wang
authors.affiliation: Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
authors.forename: W W
authors.initials: WW
authors.lastname: Qi
authors.affiliation: Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
authors.forename: E B
authors.initials: EB
authors.lastname: Ruan
authors.affiliation: Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
authors.forename: W
authors.initials: W
authors.lastname: Qu
authors.affiliation: Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
authors.forename: G J
authors.initials: GJ
authors.lastname: Wang
authors.affiliation: Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
authors.forename: H
authors.initials: H
authors.lastname: Liu
authors.affiliation: Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
authors.forename: Y H
authors.initials: YH
authors.lastname: Wu
authors.affiliation: Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
authors.forename: J
authors.initials: J
authors.lastname: Song
authors.affiliation: Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
authors.forename: L M
authors.initials: LM
authors.lastname: Xing
authors.affiliation: Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China shaozonghong_l@yeah.net.
authors.forename: Z H
authors.initials: ZH
authors.lastname: Shao
mesh_terms: D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000235:genetics* / Q000276:immunology / Q000473:pathology; D018952:Antigens, CD34 / Q000096:biosynthesis / Q000235:genetics; D017209:Apoptosis / Q000276:immunology; D051017:Apoptosis Regulatory Proteins / Q000096:biosynthesis / Q000235:genetics*; D001854:Bone Marrow Cells / Q000276:immunology / Q000378:metabolism*; D016827:CD8 Antigens / Q000096:biosynthesis / Q000235:genetics; D053222:Fas Ligand Protein / Q000096:biosynthesis / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006412:Hematopoietic Stem Cells / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D017493:Leukocyte Common Antigens / Q000096:biosynthesis / Q000235:genetics; D008297:Male
chemical_list: D018952:Antigens, CD34; D051017:Apoptosis Regulatory Proteins; D016827:CD8 Antigens; C421307:FAIM protein, human; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D017493:Leukocyte Common Antigens; C516769:PTPRC protein, human